valsartan has been researched along with DDD MPGNII in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arakawa, M; Murata, Y; Rikimaru, Y; Sasaki, Y | 1 |
Akdag, I; Filiz, G; Gullulu, M; Kahvecioglu, S; Savci, V | 1 |
Ikee, R; Kobayashi, S; Maesato, K; Mano, T; Moriya, H; Ohtake, T; Oka, M | 1 |
3 other study(ies) available for valsartan and DDD MPGNII
Article | Year |
---|---|
Drug-induced isolated visceral angioneurotic edema.
Topics: Adult; Angioedema; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diagnosis, Differential; Female; Glomerulonephritis, Membranoproliferative; Humans; Lisinopril; Renal Dialysis; Tetrazoles; Valine; Valsartan | 2005 |
Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Proliferation; Disease Models, Animal; Diuretics; Fibrosis; Glomerulonephritis, Membranoproliferative; Ki-67 Antigen; Kidney; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Spironolactone; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2006 |
Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biopsy; Creatinine; Female; Fibrosis; Glomerulonephritis, Membranoproliferative; Humans; Immunoglobulin A; Kidney Glomerulus; Losartan; Male; Middle Aged; Receptor, Angiotensin, Type 1; Retrospective Studies; Telmisartan; Tetrazoles; Valine; Valsartan; Vasodilation | 2008 |